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ABSTRACT 
Objective: To investigate and compare the efficacy of atorvastatin, etoricoxib and combination of both drugs against colon carcinogenesis in male 
wistar rats.  
Methods: Male wistar rats were divided into five groups. Group-1 served as normal control. Group-2 subcutaneously received 1,2-
dimethylhydrazine (DMH) (20 mg/kg body weight(b. w.)) and served as DMH control. Groups-3, 4 and 5 were treated with DMH once in a week for 
17 weeks. One week before the administration of DMH, group-3 and group-4 received etoricoxib (0.64 mg/kg per oral (p. o)), atorvastatin (2.5 
mg/kg subcutaneously (s. c)) respectively and group-5 received both drugs and lasted until the end of the experiment. The effect of drugs on body 
weight gain, food and water intake, haematological parameter and histopathological view of the colon was observed in the entire group of animals.  
Results: The experimental evidences showed that significant effect of the combined dose of etoricoxib and atorvastatin against DMH induced colon 
cancer by increasing the level of antioxidant enzymes. The combination was found to decrease the occurrence of multiple plaque lesions which may 
become the basis for its better chemo preventive action against the progression of colon carcinogenesis as compared to individual drugs. The 
histopathological study demonstrated that the combination treatment showed more positive effect then individual drug in prevention of colon 
carcinogenesis by reducing the inflammation, hyperplastic and dysplastic changes in colon crypt cells.  
Conclusion: This study was concluded that the combination of atorvastatin and etori coxib may be potential chemo preventive agents against DMH-
induced colon cancer and showed prominent positive effects as compared to individual drugs. 
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INTRODUCTION 
A neoplasm (tumour) is a disease that is characterized by excessive, 
uncontrolled growth and spread of structurally abnormal 
differentiated cells that can originate from any tissues of the body. 
Cancer is the leading cause of death in economically developed 
countries and the second leading cause of death in developing 
countries. Colorectal cancer is the third most commonly diagnosed 
cancer in males and the second in females [1]. Cancer of the colon is 
more common in women up to 55 years of age but thereafter is more 
common in men, rectal cancer occurs with almost equal frequency in 
both sexes up to 45 years of age, but becomes almost twice as 
common in men after the age of 65 years. About 70% of patients 
with colon cancer are over 65 years of age [2]. Aging is associated 
with increased incidence of various cancers including colorectal 
cancer. In fact, the occurrence of both non-malignant and malignant 
colorectal neoplasm increases with advancing age. In a study of men 
with prostatic carcinoma who subsequently developed colorectal 
cancer, those treated with stilboesterol had a higher incidence of 
right sided colonic cancers and a lower incidence of rectal cancers, 
than those not receiving oestrogen treatment. These data suggest 
that sex steroid hormones influence the development of colorectal 
cancer [3]. Thus due to large occurrence and serious adverse effects 
of established drugs against colon cancer, there is a need to develop 
solutions for the prevention of colon cancer occurrence. Thus, the 
present study was used to measure the chemo preventive ability of 
drugs against DMH induced colon cancer. In the very early stage of 
colon cancer, the expression of cycloxygenase-2 enzyme is increased 
[4]. It leads to increased production of prostaglandins thus leads to 
increased cell proliferation, tumour growth and resistance to 
apoptosis. Therefore, a drug from class of cycloxygenase-2 inhibitor 
named, etoricoxib was used. Cyclooxygenase-2 inhibitors exert their 
anticarcinogenic effects through inhibition of cell cycle progression, 
induction of apoptosis, inhibition of angiogenesis and metastasis [5]. 
Another drug was selected from the group of statins, since statins 
reduce not only serum cholesterol levels but also mevalonate 
synthesis by inhibiting HMG-CoA reductase. Mevalonate is a precursor 
of several major products regulating the cell cycle, including geranyl 
pyrophosphate (GPP) and farnesylpyrophosphate (FPP) [6]. 
Therefore, another drug from the class of statins named atorvastatin 
was used. Statins exert their anti-neoplastic effects through inhibition 
of tumour cell growth, inhibition of angiogenesis, induction of 
apoptosis and repression of tumour metastasis [7]. As such there is no 
literature available on treatment of colon cancer by combination of 
etoricoxib and atorvastatin, so present study was designed to evaluate 
the anti-colon cancer activity of combination of etoricoxib and 
atorvastatin on 1,2-dimethylhydrazine induced colon cancer in animals.  
MATERIALS AND METHODS 
Chemicals 
The 1,2-dimethylhydrazine was purchased from Sigma Aldrich (CAS 
No.-306-37-6), etoricoxib and atorvastatin were obtained from 
Cadila Pharmaceuticals Pvt Ltd, Ahmadabad, India.  
Animals 
Male wistar rats aged 33–35 days were used in the experiment. The 
animals were adapted to standard vivarium conditions with 
temperature 23±2o
In vivo anti-cancer activity  
C, relative humidity 60–70 %, artificial regimen 
light: dark (12:12h) (lights on from 7 a. m., light intensity 150 lux per 
cage). During the experiment, animals drank tap water ad libitum. 
The experiment was carried out according to the guidelines of the 
Committee for the Purpose of Control and Supervision of 
Experiments on Animals (CPCSEA), New Delhi, India and approved 
by the Institutional Animal Ethical Committee (IAEC No. 
1611/PO/a/12/CPCSEA) of Aditya Bangalore Institute of Pharmacy 
Education and Research, Bangalore, Karnataka, India. 
This test is widely used for testing chemo preventive ability of drugs 
against 1, 2-dimethylhydrazine induced colon carcinogenesis [8]. 
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Male Wistar rats were divided into five groups. Each group consisted 
of 6 animals. Group 1 served as normal control and group 2 received 
1,2-dimethylhydrazine (DMH) (20 mg/kg b. w,s. c) (0.5 ml per 
animal) and served as DMH control. Groups 3, 4 and 5 were treated 
with 1,2-dimethylhydrazine (DMH) (20 mg/kg b. w, s. c) once in a 
week for 17 weeks. (1,2-dimethylhydrazine at 20 mg/kg b.w. was 
dissolved in isotonic saline solution) [9]. Chemoprevention with 
drug treatment began 7 days before carcinogen administration and 
lasted until the end of the experiment (17 weeks). Group 3 and 
group 4 received etoricoxib (0.64 mg/kg b. w, p. o), atorvastatin (2.5 
mg/kg b. w, s. c) respectively and group 5 received both etoricoxib 
(0.64 mg/kg b. w, p. o), atorvastatin (2.5 mg/kg b. w, s. c) [10]. 
During the experiment, body weight gain (evaluated from 
prevention initiation until the end of the experiment), food and 
water intake of animals during 24 h were observed [11]. At the end 
of 17th
Statistical analysis 
 weeks, all the animals were kept on overnight fasting with 
drinking water ad libitum and on the next day, the blood was 
collected from the entire group by retro orbital route for 
haematological analysis. Then all the animals were quickly 
decapitated, colon tumour were excised, weighed and tumour size 
was recorded. Macroscopic changes in selected organs were 
evaluated at autopsy. Tissue samples of colon tumours were fixed in 
10% formaldehyde solution and prepared for histopathological 
analysis and enzyme estimation (superoxide dismutase, catalase, 
lipid per oxidise and normal morphological view of colon) [12-14]. 
The compiled data were shown in mean±SEM. The level of significance 
as compared to control carried out by using Dunnett’s test. The 
statistical significance was drawn at p<0.05 being significant. All 
statistical analysis was carried out using GRAPH PAD In Stat. 
RESULTS 
The effect of treatment (combination of drugs and alone) on body 
weight of animals, food and water intake of animals in DMH induced 
colon cancer was observed for 17 weeks. The final body weight of 
animals was compared to their initial body weight. All the animals of 
different groups showed the steady rise in body weight and it was 
summarized in table 1. 
  
Table 1: Effect of treatment on body weight 
Group/Treatment Initial Weight (g) Final Weight (g) Body Weight Gain (g) 
Normal Control 126.66±2.072 282.16±2.092 155.5±7.08 
DMH Control 114.5±3.488 268.83±1.606 154.33±4.93 
DMH+Etoricoxib 125.91±4.352 238.33±8.674** 112.42±3.78 
DMH+Atorvastatin 121.08±3.110 247.33±11.87** 126.25±5.46 
DMH+Etoricoxib 
+Atorvastatin 
117.75±3.582 255.5±3.704* 137.75±6.23 
The values are expressed as mean±SEM, n=6. The statistical analysis was carried out using one way ANOVA followed by Dunnet’s multiple 
comparison test where *p<0.05, **p<0.01. 
 
The data obtained for food and water intake of animals was showed 
that did not reveal any significant differences in all groups and it was 
summarized in table 2. Average daily food intake of each rat was 
between 11.52 g and 13.75 g. 
 
Table 2: Effect of treatment on daily consumption of food and water 
Group/Treatment Food consumption (gm/rat/day) Water consumption (ml/rat/day) 
Normal Control 13.75±0.4100 18.77±1.167 
DMH Control 12.48±0.3803 19.17±0.9280 
DMH+Etoricoxib 11.65±0.4819* 17.45±1.068 




The values are expressed as mean±SEM, n=6. The statistical analysis was carried out using one way ANOVA followed by Dunnet’s multiple 
comparison test where *p<0.05. 
 
Table 3: Effect of treatment on Haematological parameters of DMH induced rats 
Group/Treatment Hb (g/dl) RBC (millions/μl of 
blood) 
WBC (thousands/μl of 
blood) 
Different leukocyte count (%) 
Neutrophil Lymphocytes 
Normal Control 14.48±0.2691 7.53±0.1727 2.53±0.1136 22±1.92 76±2.312 
DMH Control 11.69±0.4380 4.21±0.2469 8.42±0.1606 46±1.83 52±0.7654 
DMH with etoricoxib 11.88±0.1380** 5.04±0.0374** 4.15±0.0960** 25±2.16** 44±1.42** 
DMH with atorvastatin 12.75±0.1787** 4.40±0.1361** 6.68±0.0939** 30±1.28** 48±2.13** 
DMH with etoricoxib and 
atorvastatin 
12.91±0.2122** 5.43±0.1619** 7.69±0.1346** 41±1.46** 62±1.68** 
The values are expressed as mean±SEM, n=6. The statistical analysis was carried out using one way ANOVA followed by Dunnet’s multiple 
comparison test where *p<0.05, **p<0.01. 
 
Haematological parameters 
The effect of treatment (combination of drugs and alone) on 
haematological parameter like haemoglobin (Hb) count, red blood 
corpuscle (RBC), white blood corpuscle (WBC) and different 
leukocyte count in DMH induced colon cancer was determined and 
summarized in table 3. 
The result showed that the RBC count in DMH control animals 
decreased when compared with normal control and groups which 
received single drug and combination of drugs. There was marked 
decreased level of Hb was observed in DMH control animals when 
compared with normal control. The significant increase of Hb level 
in group 5 was observed. The level of WBC was found to be 
markedly increased in DMH control animals. The level of WBC 
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brought down by etoricoxib alone drug treatment is more significant 
than atorvastatin alone received group and combination received 
group. The level of Neutrophil was found to be significantly 
increased in DMH control animals which gets significantly decreased 
in group received etoricoxib alone treatment as compared to 
atorvastatin alone treated group and combination treated group. 
The level of lymphocyte was found to be decreased in DMH control 
animals which further gets decreased in etoricoxib alone treated 
group and slightly increased in atorvastatin alone treated group. The 
lymphocyte count in combination treated group was found to be 
significantly increased. 
Enzyme estimation 
Preventive effect of etoricoxib and atorvastatin in male wister rats 
colon cancer with respect to enzyme was summarized in table 4. 
Lipid peroxidation was studied by measuring the formation of thio 
barbituric acid reactive substances (TBARS), lipid hydroperoxides 
(LPO), conjugated dienes (CD) and superoxide dismutase (SOD), 
catalase (CAT), glutathione peroxidase (GPX), glutathione reductase 
(GR), reduced glutathione (GSH) and malondialdehyde (MDA) in the 
liver and colonic tissues of DMH administered rats. Experimental 
results showed that decreased levels of lipid peroxidation in the 
colonic tissues, decreased activities of antioxidant enzymes like 
SOD, CAT, GPX, GR and GSH levels in the tissues on DMH 
treatment. Combination of atorvastatin and etoricoxib 
supplementation during the initiation and entire period stages of 
carcinogenesis significantly reversed these activities. The level of 
SOD was found to be markedly decreased in DMH control animals 
as compared to normal animals.  
The level of SOD was significantly increased in combination 
received group as compared to level of SOD in etoricoxib and 
atorvastatin alone treated groups. The level of CAT also found to 
be significantly decreased in DMH control animals. The level of 
CAT was found to be markedly increased in combination 
received group as compared to etoricoxib and atorvastatin alone 
treated groups. The MDA level was found to be increased in DMH 
control animals. The level of MDA was found to be slightly 
decreased in etoricoxib and atorvastatin alone treated groups as 
compared to the significant decrease shown by group etoricoxib 
and atorvastatin combination received group. 
  
Table 4: Effect of treatment on level of SOD, CAT and MDA in liver tissue of DMH induced rats 
Group/Treatment SOD (Units/mg of 
protein) 
Catalase (Units/mg of protein) MDA (nM of MDA/mg of protein) 
Normal Control 21.37±0.4326 60.45±1.068 23.32±0.5789 
DMH Control 9.45±0.0788 18.94±0.5750 52.38±1.166 
DMH with etoricoxib 13.68±0.4977** 29.31±0.6361** 40.74±0.3884** 
DMH with atorvastatin 11.24±0.1336** 34.69±0.3476** 37.68±0.6154** 
DMH with etoricoxib and atorvastatin 17.71±0.0963** 41.42±0.4373** 32.69±0.3419** 
The values are expressed as mean±SEM, n=6. The statistical analysis was carried out using one way ANOVA followed by Dunnet’s multiple 
comparison test where *p<0.05, **p<0.01. 
 
Morphological view of the colon 
Morphological view of the colon of all groups was studied and 
reported in [fig. 1] to [fig. 5]. 
 
 
Fig. 1: Normal control group 
 
 
Fig. 2: DMH control group 
 
 
Fig. 3: Etoricoxib treated group 
 
 
Fig. 4: Atorvastatin treated group 
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Fig. 5: Atorvastatin and etoricoxib combined treated group 
 
Histopathological view of the colon 
Histopathology of the colon of all groups were studied and reported 
in [fig. 6] to [fig. 10]. Etoricoxib and atorva stastin treated groups 
showed that decrease in hyperplasia and dysplasia. DMH with 
Atorvastatin and Etoricoxib group revealed that there was marked 




Fig. 6: Normal control group 
 
 
Fig. 7: DMH control group 
 
DISCUSSION 
The present study was undertaken to evaluate cytotoxic, 
chemopreventive and antioxidant activity of etoricoxib and 
atorvastatin alone and in combination by in-vivo methods. This study 
indicated that there was no significant effect of treatments on food 
and water intake of animals. The body weights of the animals of 
different groups rise steadily throughout the study. Colon cancer 
leads to myelosuppression and anaemia. 
 
 
Fig. 8: DMH and Etoricoxib group 
 
 
Fig. 9: DMH and Atorvastain group 
 
 
Fig. 10: DMH with atorvastatin and etoricoxib group 
 
The erythrocyte level was markedly decreased in DMH control 
animals (4.21 million/μl) received dose of 20 mg/kg s. c. whereas 
group treated with combination of etoricoxib at 0.64 mg/kg p. o and 
atorvastatin at 2.5 mg/kg s. c showed significantly increased 
erythrocyte level (5.43 million/μl) as compared to erythrocyte levels 
shown by etoricoxib (5.04 million/μl) and atorvastatin alone treated 
groups (4.40 million/μl). In DMH control animals the WBC level was 
found to be increased (8.42 thousand/μl). The combination treated 
group showed slight decrease in WBC level (7.69 thousand/μl) as 
compared to etoricoxib (4.15 thousand/μl) and atorvastatin alone 
treated groups (6.68 thousand/μl). The combination treated group 
showed increased Hb value (12.91 g/dl) as compared to values of 
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individual drug treated groups etoricoxib (11.88 g/dl) and 
atorvastatin (12.75 g/dl). The differential leukocytes count showed 
the significant increase in lymphocyte in combination group (62%) 
as compared to etoricoxib (44%) and atorvastatin alone treated 
groups (48%). The Neutrophil count of DMH control animals was 
found to be (46%) while combination treated group showed less 
decrease (41%) as compared to single drug treated groups. Reactive 
oxygen species plays an important role in the initiation stages colon 
carcinogenesis.  
Also results showed that the decrease in the level of SOD in DMH 
control animals (9.45 units/mg of protein) whereas, the group 
treated with combination showed significantly increased levels of 
SOD (17.71 units/mg of protein) as compared to level of SOD found 
in Etoricoxib (13.68 units/mg of protein) and Atorvastatin single 
drug treated groups (11.24 units/mg of protein). The level of CAT 
was found to be markedly decreased in DMH control animals (18.94 
units/mg of protein) however, the group received combination 
showed increased level of CAT (41.42 units/mg of protein) as 
compared to levels observed in groups received individual drug 
treatments of Etoricoxib (29.31 units/mg of protein) and 
Atorvastatin (34.69 units/mg of protein). Morphological view of the 
colon showed that the appearance of multiple plaque lesions (MPLs). 
MPLs were recognized as either raised or non-raised lesions with 
identifiable tissue growth in carcinogen treated animals. The colon of 
DMH control animal showed highest occurrence of MPLs than the 
occurrence of MPLs in colon of Etoricoxib and Atorvastatin alone 
treated animals while there was still less number of MPLs found on 
colon of animals received combination of Etoricoxib and Atorvastatin. 
Observations of histopathological study indicated that there was 
marked dysplasia and hyperplasia in DMH control animals. The crypts 
were found to be enlarged along with distinct inflammatory changes. 
While animals received Etoricoxib alone showed decrease in 
hyperplasia and dysplasia indicated its efficacy as a chemo preventive 
agent. Histopathological results revealed that there was marked 
regression in inflammation and moderate reduction in hyperplasia in 
animals treated with combination of Etoricoxib and Atorvastatin. Also 
the size and shape of the cells were found to be nearly uniform with 
reduction in occurrence of aberrant crypt foci. 
CONCLUSION 
The experimental evidences showed that significant effect in in-vivo 
study of chemoprevention of combined dose of etoricoxib and 
atorvastatin against DMH induced colon cancer by increasing the 
level of antioxidant enzymes. The combination was found to 
markedly decrease the occurrence of multiple plaque lesions which 
may become basis for its better chemo preventive action against the 
progression of colon carcinogenesis as compared to individual 
drugs. The Histopathological study demonstrated that combination 
treatment showed more positive effect then individual drugs in 
prevention of colon carcinogenesis by reducing the inflammation, 
hyper plastic and dysplastic changes in colon crypt cells. Hence, it 
was concluded that the combination of Etoricoxib and Atorvastatin 
showed prominent positive effects as compared to individual drugs. 
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